Document is current

Article History

Accepted: 3 October 2021

First Online: 31 October 2021

Declarations

:

: This research received no external funding.

: FP has participated in speakers bureaus for Angelini, Basilea Pharmaceutica, Gilead, Hikma, Merck Sharp & Dohme, Nordic Pharma, Pfzer and Sanof Aventis, and in advisory boards for Angelini, Basilea Pharmaceutica, Correvio, Gilead, Hikma, Merck Sharp & Dohme, Nordic Pharma, Novartis, Pfzer, Shionogi and Thermo-Fisher. SP has participated in speakers bureaus for Kedrion, Roche, Novo Nordisk, Bayer, Sobi, CSL Behring, Pfizer, and Takeda. Pier Giorgio Cojutti and Ezio Zanon have no conflicts of interest to declare.

: The study protocol was approved by each institution’s Ethical Committee and was conducted in accordance with the principles of the Declaration of Helsinki and with local laws and regulations. All patients provided written informed consent.

: In light of the retrospective nature of this study, written informed consent was waived, according to the institutional policies for studies with a retrospective design.

: Not applicable.

: Not applicable.

: Not applicable.

: PGC and FP conceptualised the study, performed the analysis and drafted the manuscript. EZ and SP supervised the project and reviewed the entire contents of the manuscript. All authors have read and agree to the published version of the manuscript.